Gilead Sciences Inc. (NASDAQ: GILD) released third-quarter earnings report after markets closed on Tuesday. Despite negative news coming out on Tuesday with former presidential candidate Bernie Sanders taking a shot at the healthcare sector,…
Although Gilead has been falling for about a year now, the valuation is looking more favorable — assuming Gilead is not a value trap. The earnings report will help shed some light on where…
Shares of InspireMD more than doubled in Tuesday’s session after the company announced followup data from its Paradigm-101 trial of the CGuard Embolic Prevention System.
Organovo Holdings shares saw a handy gain on Tuesday after the bio-printer announced that it received a strong consumer response from its ExVive Human Kidney Tissue service.
As Pfizer is a major player in the pharmaceutical industry, this earnings report is important in setting a direction that other companies can rally behind.
The relentless populist rhetoric has lowered the prices on some of the top pharmaceutical companies, and long-term growth and income investors have a chance to buy some great stocks on sale.
Ophthotech Corp. (NASDAQ: OPHT) is watching its shares rise in Monday’s trading session after the company reported results from its mid-stage trial of Fovista in combination with Lucentis for the treatment of wet age-related…
Pfizer is scheduled to release its third-quarter financial results before the markets open on Tuesday.
Shares of Ariad Pharmaceuticals saw a modest gain early Monday after the company announced a recent FDA decision.
Genocea Biosciences shares saw a handy gain early Friday following the release of mid-stage results from its genital herpes treatment.
Opexa Therapeutics Inc. (NASDAQ: OPXA) shares were in free fall Friday morning after the company reported results from its mid-stage trial for the treatment of secondary progressive multiple sclerosis. The company said that its…
AbbVie reported mixed third-quarter financial results and a dividend hike before the markets opened on Friday.
Though Amgen reported better-than-expected third-quarter results on Thursday, shares sank early Friday.
Myovant Sciences entered the market near the high end of its expected price range for its initial public offering.
Community Health Systems is looking and acting like it is an implosion waiting to happen. The company has projected a loss for its third-quarter earnings report.
